Confirmatory ZUMA-2 trial data led to full FDA approval of brexucabtagene autoleucel for patients with relapsed or refractory mantle cell lymphoma.
Updated results from the ZUMA-2 trial confirmed the therapy's benefit, including in BTKi-naïve patients, after its accelerated approval in 2020.
The U.S. Food and Drug Administration (FDA) has granted traditional full approval to the CAR-T cell therapy Tecartus ...
– At Almost Four Years of Follow-up in the Pivotal ZUMA-2 Study, Median Overall Survival was 46.4 Months, Supporting Long-Term Response in Adult Patients with Relapsed/Refractory (R/R) Mantle Cell ...
An examination of patient outcomes from the ZUMA-2 trial creates new questions about treatment sequencing. An fresh look at trial results that propelled the only FDA approval of a chimeric antigen ...
Tecartus is safe and effective in real-world patients with relapsed/refractory mantle cell lymphoma, regardless of the presence of high-risk features. For patients with relapsed/refractory mantle cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results